Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical pharmacological study of luseogliflozin in patients with type 2 diabetes mellitus (glycemic variability by CGM)
jRCT1080222497Phase 4
- Sponsor
- Taisho Pharmaceutical
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Luseogliflozin with Placebo (2 arms). Primary endpoint: Glycemic variability by continuous glucose monitoring.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080222497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222497.